With eyes on first al­lo­gene­ic CAR-T ap­proval, Pre­ci­sion touts 100% re­sponse in 's­mall niche' pop­u­la­tion

Pre­ci­sion Bio­Sciences has grand reg­u­la­to­ry am­bi­tions for its lead pro­gram: first al­lo­gene­ic CAR-T ther­a­py on the mar­ket, but the biotech will have to shore up safe­ty con­cerns of its drug as four deaths were re­port­ed in a Phase I/IIa tri­al.

En route to meet­ing with the FDA lat­er this year on po­ten­tial reg­is­tra­tion strat­e­gy, the North Car­oli­na biotech is out with new in­ter­im Phase I/IIa clin­i­cal da­ta on its prized pos­ses­sion, dubbed PB­CAR0191. The an­ti-CD19 can­di­date is be­ing test­ed in pa­tients with re­lapsed or re­frac­to­ry ag­gres­sive lym­phomas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER